Veraxa Biotech advances bispecific ADC program VXA-222 into next development phase after OmniAb milestonePUBT·2 days ago, 03:17 PMVRXA+0.51%OABI+2.31%
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAbUnusual Whales·Jul 27 at 06:02 AMVRXA+0.51%OABI+2.31%
OmniAb files initial beneficial ownership statement for COO Amechi Ekeke NwachukuPUBT·Jul 13 at 07:08 AMOABI+2.31%
We're Not Very Worried About OmniAb's (NASDAQ:OABI) Cash Burn RateSimplywall·Jun 30 at 06:51 AMOABI+2.31%
OmniAb shareholders elect Cochran, Foehr as Class I directors at annual meetingPUBT·Jun 18 at 03:29 PMOABI+2.31%
OmniAb | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 14.43 MEarnings Watch·May 7 at 03:55 PMOABI+2.31%
